Please login to the form below

Not currently logged in
Email:
Password:

Ethicon BLA for surgical drug-device combo

Johnson & Johnson's Ethicon subsidiary has submitted a Biologic License Application to the US FDA for a device that also contains prescription drugs
Reflecting a growing trend toward the development and marketing of devices that also contain prescription drugs, Johnson & Johnson's (J&J) Ethicon subsidiary has submitted a Biologic License Application (BLA) to the US Food and Drug Administration (FDA) for the Fibrin Pad, which combines biomaterials and the plasma-derived biologics Human Fibrinogen and Human Thrombin to reduce bleeding during surgery.

The submission "is an excellent example of convergence within Johnson & Johnson, bringing together our medical device and pharmaceutical expertise," said Dr Jim Hart, vice president medical affairs, Ethicon.

The pad is intended for use as an adjunct to homeostasis when surgical methods for controlling bleeding are ineffective or impractical. Specifically, the BLA seeks clearance for use of the pad during retroperitoneal, intra-abdominal, pelvic, and (non cardiac) thoracic surgery.

The marketing application centres around data from a randomised, controlled clinical study that tested the Fibrin Pad as an adjunct to hemostasis in soft tissue bleeding.

Ethicon licensed the fibrin sealant biologicals used in the product from Omrix Biopharmaceuticals, a company focused on biosurgical and passive immunotherapy products.

Omrix has estimated that there is a potential $400m global market opportunity for the Fibrin Pad. 

22nd November 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

Lars Bruening
Shaping healthcare
Bayer’s Lars Bruening talks about moving to the UK as the market works its way through a series of seismic changes...
No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...

Infographics